Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$8.51 USD

8.51
2,874,572

-0.10 (-1.16%)

Updated Jan 14, 2025 04:00 PM ET

After-Market: $8.52 +0.02 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.35%
2Buy18.11%
3Hold9.74%
4Sell5.34%
5Strong Sell2.80%
S&P50011.41%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Sundeep Ganoria headshot

Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death

by Sundeep Ganoria

The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.

Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?

by Zacks Equity Research

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates

by Zacks Equity Research

The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.

NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines

by Zacks Equity Research

Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M

by Zacks Equity Research

NVAX intends to use the payment from Novo to advance the development of its vaccine pipeline. The deal is expected to be closed by the end of this year.

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

by Zacks Equity Research

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Sundeep Ganoria headshot

Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS

by Sundeep Ganoria

President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data

by Zacks Equity Research

NVAX and RNA are in the spotlight following Q3 results and study data, respectively.

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

by Zacks Equity Research

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.

Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

by Ahan Chakraborty

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.

Novavax to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA to remove the clinical hold on its two vaccine programs.

Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novavax (NVAX) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

In the most recent trading session, Novavax (NVAX) closed at $10.07, indicating a -1.76% shift from the previous trading day.

Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

In the closing of the recent trading day, Novavax (NVAX) stood at $10, denoting a -1.19% change from the preceding trading day.

Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?

by Zacks Equity Research

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

Novavax (NVAX) closed at $10.35 in the latest trading session, marking a +1.97% move from the prior day.

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

by Zacks Equity Research

VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.

Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold

by Zacks Equity Research

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.